Antiviral resistance during the 2009 influenza A H1N1 pandemic: Public health, laboratory, and clinical perspectives

The Lancet Infectious Diseases

Volumn 12, Issue 3, 2012, Pages 240-248

  Hurt, Aeron C ^a   Chotpitayasunondh, Tawee ^b   Cox, Nancy J ^c   Daniels, Rod ^d   Fry, Alicia M ^c   Gubareva, Larisa V ^c   Hayden, Frederick G ^e,f   Hui, David S ^g   Hungnes, Olav ^h   Lackenby, Angie ⁱ   Lim, Wilina ^j   Meijer, Adam ^k   Penn, Charles ^l   Tashiro, Masato ^m   Uyeki, Timothy M ^m   Zambon, Maria ⁱ  

^a WHO COLLABORATING CENTRE FOR REFERENCE AND RESEARCH ON INFLUENZA   (Australia)

^b MINISTRY OF PUBLIC HEALTH   (Thailand)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^e UNIVERSITY OF VIRGINIA   (United States)

^f WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^g CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^h NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

ⁱ PUBLIC HEALTH ENGLAND   (United Kingdom)

^j Public Health Laboratory Centre   (China)

^k NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^l WORLD HEALTH ORGANIZATION   (Switzerland)

^m NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; LANINAMIVIR; OSELTAMIVIR; PERAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR;

2009 H1N1 INFLUENZA; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; CLINICAL ASSESSMENT; HUMAN; IMMUNE DEFICIENCY; INFLUENZA VIRUS A H1N1; LABORATORY TEST; NONHUMAN; PANDEMIC; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; THERAPY RESISTANCE; TREATMENT DURATION; VIRUS REPLICATION; VIRUS TRANSMISSION; VIRUS VIRULENCE;

EID: 84857190187     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(11)70318-8     Document Type: Review

References (99)

1. Meijer A, Lackenby A, Hay A, Zambon M Influenza antiviral susceptibility monitoring activities in relation to national antiviral stockpiles in Europe during the winter 2006/2007 season. Euro Surveill 2007, 12:3-4.
2. Reddy D Responding to pandemic (H1N1) 2009 influenza: the role of oseltamivir. J Antimicrob Chemother 2010, 65(suppl 2):35-40.
3. Gubareva LV, Trujillo AA, Okomo-Adhiambo M, et al. Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro. Antivir Ther 2010, 15:1151-1159.
4. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000, 355:1845-1850.
5. Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 2001, 183:523-531.
6. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. JAMA 2000, 283:1016-1024.
7. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J 2001, 20:127-133.
8. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004, 364:759-765.
9. Stephenson I, Democratis J, Lackenby A, et al. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis 2009, 48:389-396.
10. Tamura D, Sugaya N, Ozawa M, et al. Frequency of drug-resistant viruses and virus shedding in pediatric influenza patients treated with neuraminidase inhibitors. Clin Infect Dis 2011, 52:432-437.
11. Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis 1998, 178:1257-1262.
12. Gubareva LV, Kaiser L, Hayden FG Influenza virus neuraminidase inhibitors. Lancet 2000, 355:827-835.
13. Hurt AC, Holien JK, Parker M, Barr IG Oseltamivir resistance and the H274Y neuraminidase mutation in seasonal, pandemic and highly pathogenic influenza viruses. Drugs 2009, 69:2523-2531.
14. Meijer A, Lackenby A, Hungnes O, et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis 2009, 15:552-560.
15. Dharan NJ, Gubareva LV, Meyer JJ, et al. Infections with oseltamivir-resistant influenza A(H1N1) virus in the United States. JAMA 2009, 301:1034-1041.
16. Ciancio BC, Meerhoff TJ, Kramarz P, et al. Oseltamivir-resistant influenza A(H1N1) viruses detected in Europe during season 2007-08 had epidemiologic and clinical characteristics similar to co-circulating susceptible A(H1N1) viruses. Euro Surveill 2009, 14:19412.
17. Besselaar TG, Naidoo D, Buys A, et al. Widespread oseltamivir resistance in influenza A viruses (H1N1), South Africa. Emerg Infect Dis 2008, 14:1809-1810.
18. Hurt AC, Ernest J, Deng Y, et al. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Res 2009, 83:90-93.
19. Collins PJ, Haire LF, Lin YP, et al. Structural basis for oseltamivir resistance of influenza viruses. Vaccine 2009, 27:6317-6323.
20. Bloom JD, Gong LI, Baltimore D Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 2010, 328:1272-1275.
21. Carr J, Ives J, Kelly L, et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res 2002, 54:79-88.
22. Herlocher ML, Carr J, Ives J, et al. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res 2002, 54:99-111.
23. Herlocher ML, Truscon R, Elias S, et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 2004, 190:1627-1630.
24. Update on oseltamivir resistance to influenza A(H1N1)2009 viruses WHO, (accessed Dec 15, 2011). http://www.who.int/influenza/2011_04_08_weekly_web_update_oseltamivir_resistance.pdf.
25. IMS customer portal IMS Health, (accessed Dec 1, 2011). https://websolutions.imshealth.com/EB2/User/Validate_UserID.aspx?TARGET=$SM$https://customerportal.imshealth.com/portal/site/imsportal.
26. Ujike M, Ejima M, Anraku A, et al. Monitoring and characterization of oseltamivir-resistant pandemic (H1N1) 2009 virus from May 2009 to February 2010, Japan. Emerg Infect Dis 2011, 17:470-479.
27. Meijer A, Jonges M, Abbink F, et al. Oseltamivir-resistant pandemic A(H1N1) 2009 influenza viruses detected through enhanced surveillance in the Netherlands, 2009-2010. Antiviral Res 2011, 92:81-89.
28. Hurt AC, Deng Y, Ernest J, et al. Oseltamivir-resistant influenza viruses circulating during the first year of the influenza A(H1N1) 2009 pandemic in the Asia-Pacific region, March 2009 to March 2010. Euro Surveill 2011, 16:19770.
29. Leung TW, Tai AL, Cheng PK, Kong MS, Lim W Detection of an oseltamivir-resistant pandemic influenza A/H1N1 virus in Hong Kong. J Clin Virol 2009, 46:298-299.
30. Zonis Z, Engelhard D, Hindiyeh M, et al. Community-acquired oseltamivir-resistant pandemic (H1N1) 2009 in child, Israel. Emerg Infect Dis 2010, 16:1045-1046.
31. Wolfe C, Greenwald I, Chen L Pandemic (H1N1) 2009 and oseltamivir resistance in hematology/oncology patients. Emerg Infect Dis 2010, 16:1809-1811.
32. Moore C, Galiano M, Lackenby A, et al. Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit. J Infect Dis 2011, 203:18-24.
33. Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis-North Carolina, 2009. MMWR Morb Mortal Wkly Rep 2009, 58:969-972.
34. Le QM, Wertheim HF, Tran ND, van Doorn HR, Nguyen TH, Horby P A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N Engl J Med 2010, 362:86-87.
35. Hurt AC, Hardie K, Wilson NJ, et al. Community transmission of oseltamivir-resistant A(H1N1)pdm09 influenza. N Engl J Med (in press).
36. Lackenby A, Moran GJ, Pebody R, et al. Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11. Euro Surveill 2011, 16:19784.
37. Duan S, Boltz DA, Seiler P, et al. Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower transmissibility and fitness in ferrets. PLoS Pathog 2010, 6:e1001022.
38. Hamelin ME, Baz M, Abed Y, et al. Oseltamivir-resistant pandemic A/H1N1 virus is as virulent as its wild-type counterpart in mice and ferrets. PLoS Pathog 2010, 6:e1001015.
39. Kiso M, Shinya K, Shimojima M, et al. Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses. PLoS Pathog 2010, 6:e1001079.
40. Seibert CW, Kaminski M, Philipp J, et al. Oseltamivir-resistant variants of the 2009 pandemic H1N1 influenza A virus are not attenuated in the guinea pig and ferret transmission models. J Virol 2010, 84:11219-11226.
41. Memoli MJ, Davis AS, Proudfoot K, et al. Multidrug-resistant 2009 pandemic influenza A(H1N1) viruses maintain fitness and transmissibility in ferrets. J Infect Dis 2011, 203:348-357.
42. Chen H, Smith GJ, Li KS, et al. Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc Natl Acad Sci USA 2006, 103:2845-2850.
43. Jayaraman A, Pappas C, Raman R, et al. A single base-pair change in 2009 H1N1 hemagglutinin increases human receptor affinity and leads to efficient airborne viral transmission in ferrets. PLoS One 2011, 6:e17616.
44. Bloom JD, Nayak JS, Baltimore D A computational-experimental approach identifies mutations that enhance surface expression of an oseltamivir-resistant influenza neuraminidase. PLoS One 2011, 6:e22201.
45. Influenza virological updates WHO, (accessed Dec 1, 2011). http://www.who.int/influenza/gisrs_laboratory/updates/en/index.html.
46. EuroFlu weekly electronic bulletin, influenza season 2010-2011 EUROFLU, (accessed Oct 3, 2011). http://www.euroflu.org/cgi-files/bulletin_v2.cgi?season=2010&inter=n&menu=y.
47. Weekly influenza surveillance overview ECDC, (accessed Oct 3, 2011). http://ecdc.europa.eu/en/publications/surveillance_reports/influenza/Pages/weekly_influenza_surveillance_overview.aspx.
48. Chinese National Influenza Center, surveillance CNIC, (accessed Oct 3, 2011). http://www.cnic.org.cn/eng/surveillance.php.
49. Centers for Disease Control and Prevention, flu activity and surveillance CDC, (accessed Oct 3, 2011). http://www.cdc.gov/flu/weekly/fluactivitysurv.htm.
50. Public Health Agency of Canada, FluWatch PHAC, (accessed Oct 3, 2011). http://www.phac-aspc.gc.ca/fluwatch/index-eng.php.
51. Influenza Australian Government DoHaA, (accessed Oct 3, 2011). http://www.health.gov.au/internet/main/publishing.nsf/Content/cda-surveil-ozflu-flucurr.htm.
52. Lackenby A, Powers C, Elliott AJ, et al. Antiviral susceptibility of pandemic influenza in a self-sampling, oseltamivir treated community surveillance scheme in the UK. Options for the Control of Influenza VII; Hong Kong, SAR, China; Sept 3-7, 2010. Abstract P-186.
53. Lackenby A, Hungnes O, Dudman S, et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill 2008, 13:5.
54. Nguyen HT, Sheu TG, Mishin VP, Klimov AI, Gubareva LV Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays. Antimicrob Agents Chemother 2010, 54:3671-3677.
55. Santos L, Correia V, Giria M, et al. Genetic and antiviral drug susceptbility profiles of pandemic A(H1N1)v influenza virus circulating in Portugal. Options for the Control of Influenza VII; Hong Kong, SAR, China; Sept 3-7, 2010. Abstract O-851.
56. Rousset D, Le Goff J, Abou-Jaoude G, et al. Emergence of successive mutations in the neuraminidase of the pandemic H1N1 virus respectively associated with oseltamivir resistance and reduced susceptbility to both oseltamivir and zanamivir under treatment with neuraminidase inhibitors. Options for the Control of Influenza VII; Hong Kong, SAR, China; Sept 3-7, 2010. Abstract P-198.
57. van der Vries E, Stelma FF, Boucher CA Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus. N Engl J Med 2010, 363:1381-1382.
58. Nguyen HT, Fry AM, Loveless PA, Klimov AI, Gubareva LV Recovery of a multidrug-resistant strain of pandemic influenza A 2009 (H1N1) virus carrying a dual H275Y/I223R mutation from a child after prolonged treatment with oseltamivir. Clin Infect Dis 2010, 51:983-984.
59. Hurt A, Lee R, Leang S, et al. Increased detection in Australia and Singapore of a novel influenza A(H1N1)2009 variant with reduced oseltamivir and zanamivir sensitivity due to a S247N neuraminidase mutation. Euro Surveill 2011, 16:19884.
60. Hurt AC, Leang SK, Speers DJ, Barr IG, Maurer-Stroh S;. Mutations I117V and I117M and oseltamivir sensitivity of pandemic (H1N1) 2009 viruses. Emerg Infect Dis (in press).
61. Saito R, Sato I, Suzuki Y, et al. Reduced effectiveness of oseltamivir in children infected with oseltamivir-resistant influenza A (H1N1) viruses with His275Tyr mutation. Pediatr Infect Dis J 2010, 29:898-904.
62. Kawai N, Ikematsu H, Iwaki N, et al. Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation. J Infect 2009, 59:207-212.
63. Matsuzaki Y, Mizuta K, Aoki Y, et al. A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir. Virol J 2010, 7:53.
64. He G, Massarella J, Ward P Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet 1999, 37:471-484.
65. Peng AW, Milleri S, Stein DS Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation. Antimicrob Agents Chemother 2000, 44:1974-1976.
66. Sugaya N, Tamura D, Yamazaki M, et al. Comparison of the clinical effectiveness of oseltamivir and zanamivir against influenza virus infection in children. Clin Infect Dis 2008, 47:339-345.
67. Sugaya N, Mitamura K, Yamazaki M, et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis 2007, 44:197-202.
68. Speers DJ, Williams SH, Pinder M, Moody HR, Hurt AC, Smith DW Oseltamivir-resistant pandemic (H1N1) 2009 influenza in a severely ill patient: the first Australian case. Med J Aust 2010, 192:166-168.
69. Suhaila M, Tang JW, Lee HK, et al. Mixtures of oseltamivir-sensitve and -resistant pandemic influenza A/H1N1/2009 viruses in immunocompromised hospitalized children. Pediatr Infect Dis J 2011, 30:625-627.
70. Lackenby A, Democratis J, Siqueira MM, Zambon MC Rapid quantitation of neuraminidase inhibitor drug resistance in influenza virus quasispecies. Antivir Ther 2008, 13:809-820.
71. Deng YM, Caldwell N, Hurt A, et al. A comparison of pyrosequencing and neuraminidase inhibition assays for the detection of oseltamivir-resistant pandemic influenza A(H1N1) 2009 viruses. Antiviral Res 2011, 90:87-91.
72. Deyde VM, Okomo-Adhiambo M, Sheu TG, et al. Pyrosequencing as a tool to detect molecular markers of resistance to neuraminidase inhibitors in seasonal influenza A viruses. Antiviral Res 2009, 81:16-24.
73. Deyde VM, Sheu TG, Trujillo AA, et al. Detection of molecular markers of drug resistance in 2009 pandemic influenza A (H1N1) viruses by pyrosequencing. Antimicrob Agents Chemother 2010, 54:1102-1110.
74. Gianella S, Richman DD Minority variants of drug-resistant HIV. J Infect Dis 2010, 202:657-666.
75. Hurt AC, Holien JK, Parker M, Kelso A, Barr IG Zanamivir-resistant influenza viruses with a novel neuraminidase mutation. J Virol 2009, 83:10366-10373.
76. Okomo-Adhiambo M, Nguyen HT, Sleeman K, et al. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses. Antiviral Res 2010, 85:381-388.
77. Graitcer SB, Gubareva LV, Kamimoto L, et al. Characterization of patients with oseltamivir-resistant pandemic (H1N1) 2009, United States. Emerg Infect Dis 2011, 17:255-257.
78. Tramontana AR, George B, Hurt AC, et al. Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis 2010, 16:1068-1075.
79. Valinotto LE, Diez RA, Barrero PR, Farias JA, Lopez EL, Mistchenko AS Emergence of intratreatment resistance to oseltamivir in pandemic influenza A H1N1 2009 virus. Antivir Ther 2010, 15:923-927.
80. Inoue M, Barkham T, Leo YS, et al. Emergence of oseltamivir-resistant pandemic (H1N1) 2009 virus within 48 hours. Emerg Infect Dis 2010, 16:1633-1636.
81. Campbell AP, Jacob ST, Kuypers J, et al. Respiratory failure caused by 2009 novel influenza A/H1N1 in a hematopoietic stem-cell transplant recipient: detection of extrapulmonary H1N1 RNA and use of intravenous peramivir. Ann Intern Med 2010, 152:619-620.
82. Nguyen JT, Hoopes JD, Le MH, et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 2010, 5:e9332.
83. Duval X, van der Werf S, Blanchon T, et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med 2010, 7:e1000362.
84. Petersen E, Keld DB, Ellermann-Eriksen S, et al. Failure of combination oral oseltamivir and inhaled zanamivir antiviral treatment in ventilator- and ECMO-treated critically ill patients with pandemic influenza A (H1N1)v. Scand J Infect Dis 2011, 43:495-503.
85. Fraaij PL, van der Vries E, Beersma MF, et al. Evaluation of the antiviral response to zanamivir administered intravenously for treatment of critically ill patients with pandemic influenza A (H1N1) infection. J Infect Dis 2011, 204:777-782.
86. Gaur AH, Bagga B, Barman S, et al. Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. N Engl J Med 2010, 362:88-89.
87. Dulek DE, Williams JV, Creech CB, et al. Use of intravenous zanamivir after development of oseltamivir resistance in a critically ill immunosuppressed child infected with 2009 pandemic influenza A (H1N1) virus. Clin Infect Dis 2010, 50:1493-1496.
88. Elbahlawan L, Gaur AH, Furman W, et al. Severe H1N1-associated acute respiratory failure in immunocompromised children. Pediatr Blood Cancer 2011, 57:625-628.
89. WHO guidelines for pharmacological management of pandemic influenza A(H1N1) 2009 and other influenza viruses. Revised February 2010 WHO, (accessed Oct 3, 2011). http://www.who.int/csr/resources/publications/swineflu/h1n1_guidelines_pharmaceutical_mngt.pdf.
90. Renaud C, Boudreault AA, Kuypers J, et al. H275Y mutant pandemic (H1N1) 2009 virus in immunocompromised patients. Emerg Infect Dis 2011, 14:653-660.
91. Wiebe C, Reslerova M, Komenda P, Bueti J, Rigatto C, Sood MM Atypical clinical presentation of H1N1 influenza in a dialysis patient. Lancet 2009, 374:1300.
92. Gooskens J, Jonges M, Claas EC, Meijer A, Kroes AC Prolonged influenza virus infection during lymphocytopenia and frequent detection of drug-resistant viruses. J Infect Dis 2009, 199:1435-1441.
93. Chen LF, Dailey NJ, Rao AK, et al. Cluster of oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infections on a hospital ward among immunocompromised patients-North Carolina, 2009. J Infect Dis 2011, 203:838-846.
94. Mandelboim M, Hindiyeh M, Meningher T, Mendelson E Possible transmission of pandemic (HIN1) 2009 virus with oseltamivir resistance. Emerg Infect Dis 2010, 16:873-874.
95. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009, 15:1143-1238.
96. Ison MG Epidemiology, prevention, and management of influenza in patients with hematologic malignancy. Infect Disord Drug Targets 2011, 11:34-39.
97. Kumar D, Morris MI, Kotton CN, et al. Guidance on novel influenza A/H1N1 in solid organ transplant recipients. Am J Transplant 2010, 10:18-25.
98. Epidemic- and pandemic-prone acute respiratory diseases: infection prevention and control in health care WHO, (accessed Oct 3, 2011). http://www.who.int/csr/resources/publications/EPR_AM3_E3.pdf.
99. Prevention strategies for seasonal influenza in healthcare settings: guidelines and recommendations CDC, (accessed Oct 3, 2011). http://www.cdc.gov/flu/professionals/infectioncontrol/healthcaresettings.htm.